DSIP
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
DSIP — Delta Sleep-Inducing Peptide — is one of the few sleep compounds that isn’t a drug bolted onto your nervous system from the outside. It’s a naturally occurring neuropeptide your own brain makes. It was discovered in 1977 when Schoenenberger and Monnier pulled it from the blood of rabbits whose brains had been stimulated into deep, delta-wave (slow-wave) sleep — and named it for exactly what it appeared to do: induce delta sleep.
Structurally it’s a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) exact sequence. The pitch is appealing: a signal the body already uses to organize deep sleep, given back to you. The honest reality is more interesting and more humble than the marketing — DSIP has a real but thin human track record, and the evidence is genuinely mixed. This article gives you the real picture so you can decide with your eyes open.
DSIP sits at the sleep anchor of the OHM cognitive/sleep cluster. Where Selank calms the mental noise that keeps you up and Semax is daytime clarity, DSIP is aimed straight at sleep itself — specifically at sleep architecture (how deep and how consolidated), not at sedation.
What does it do in my body?
Here’s the part most write-ups skip: DSIP’s mechanism is genuinely under-characterized, and the honest sources say so. A 2009 anaesthesia study flatly noted DSIP “lacks documented intrinsic biological activity in controlled studies” (PMID 19142086) — meaning there is no clean, agreed-upon receptor story for it the way there is for, say, a benzodiazepine or melatonin.
What’s proposed, across the literature:
- Modulation of delta-wave (slow-wave) sleep architecture — the original rationale and the namesake effect. The idea is that DSIP nudges sleep toward deeper, more consolidated stages rather than knocking you unconscious. mechanism.
- HPA-axis / stress-hormone modulation — DSIP has been studied for effects on the cortisol/ACTH stress axis. The human data here are themselves mixed: one study found DSIP decreased ACTH (Chiodera 1994, PMID 7698722) while another found no effect on CRH- or meal-induced ACTH/cortisol (Späth-Schwalbe 1995, PMID 7777652). So the “stress-buffering” story is plausible but unproven.
- Possible weak opiate-receptor activity — proposed off the back of the withdrawal-syndrome work (below), where DSIP blunted somatic withdrawal symptoms. mechanism.
- Antioxidant / stress-protective / thermoregulatory effects in preclinical models.
The takeaway: DSIP behaves like a sleep- and stress-modulator — it seems to do more in a disturbed system than a healthy one — but the receptor-level mechanism is an open question, not settled science. That uncertainty is part of why it grades Tier C.
How can it help me?
- Best fit: People chasing deeper, more consolidated sleep — especially when stress, a shifted sleep phase, or “wired-but-tired” is the limiter. The peptide for the sleep-architecture question, not the knock-you-out question. The specific symptom phenotype to recognize (added 2026-06-24): wired but tired in the evening + consistently waking between 2-4 AM + poor recovery despite “doing everything right” on sleep hygiene + nutrition + exercise. The 2-4 AM wake pattern is a direct read on cortisol dysregulation (elevated nighttime cortisol from a flattened diurnal rhythm).
- Where the science stands: Small and old: a handful of 1980s–early-90s human studies (mostly one investigator group), split between positive open-label results and weak/null double-blind results. No modern RCT. Tier C.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
DSIP is one of the more benign molecules in its record — the limitation is evidence, not toxicity.
- Headache — the one AE that actually shows up (a few patients in the Dick withdrawal cohort). Usually minor.
- No dependence, no tolerance, no withdrawal, no morning hangover/sedation documented — unlike sleeping pills, this is not a CNS-depressant profile.
- No hepatotoxicity or cardiovascular signal in the (small) human record.
- The realistic “side effect” for most people is simpler: it may just not do much. The double-blind data make that a genuine possibility, so don’t keep chasing the dose upward if a fair trial does nothing.
Storage: refrigerate after reconstitution; protect from light; use within the typical compounding/label window.
Regulatory status: US: Not FDA-approved for any indication. Not a controlled substance. As of September 29, 2023, FDA placed DSIP (nominated as “Emideltide”) on the Category 2 bulk-drug-substances list — substances FDA has flagged with significant-safety-concern questions, which means it is not permitted for 503A compounding. (Semax and Selank acetate were added in the same action.) Practically: DSIP is not available through a compounding pharmacy the way some peptides are — it’s accessible only through the research-chemical channel, “not for human consumption.” This is an active regulatory area; the broader peptide-compounding question is on the FDA’s pharmacy-compounding advisory agenda.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution. DSIP ships as a lyophilized powder. Reconstitute with bacteriostatic water; refrigerate after mixing; protect from light.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Route. The 1980s clinical studies used intravenous DSIP in a clinical setting. The modern at-home community route is subcutaneous injection — that’s a real gap to be aware of: the home protocol isn’t the route the trials validated.
Community-standard protocol (vendor-monograph / practitioner tier —, not trial-derived):
- Dose: ~100–250 mcg, most commonly starting at 100 mcg and titrating up by response.
- Timing: 30–60 minutes before bed, once nightly.
- Cycle: typically run in short blocks (roughly 1–4 weeks) rather than indefinitely, then assess. against a primary protocol source.
What to expect: and what not to. DSIP is not a sedative. It won’t drop you like a benzodiazepine or a strong dose of trazodone. The reported effect is deeper, more consolidated sleep and easier mornings — and given the evidence, it’s reasonable to treat your own response over 1–2 weeks as the real test. If nothing changes, it isn’t working for you; the data say that’s a real possibility.
Use it as a reset tool, not a crutch. Jones (2026) articulates the cleanest rule for how to think about DSIP cycling: “Use it for a rough stretch — 4 to 6 weeks during high stress, post-surgery, loss, life disruption — then you get off it. The body adapts, so use it like a reset tool, not a crutch to continually get good sleep.” Mechanistically he reframes DSIP not as literally reproducing delta waves but as “sending a biochemical signal that your system interprets as ‘time to get to deep restorative sleep’” — useful framing for explaining what users actually feel vs. what’s electrically happening in the EEG. Patients tracking on Oura rings often see deep-sleep numbers move within a few nights. Maps cleanly to the short-block cycling already in the protocol above.
The nervous-system-first hierarchy framing (added 2026-06-24). A useful editorial reframe: DSIP is best understood not as a sleep supplement but as a nervous-system-regulation tool whose highest-leverage downstream effect is deep sleep. The mechanistic logic: chronic stress → cortisol elevated/dysregulated → sympathetic dominance + reduced parasympathetic tone → blood flow redirected from digestion + healing toward survival → mitochondrial efficiency declines → sleep architecture is disrupted → inflammatory signaling becomes altered → recovery capacity drops. DSIP supports the regulatory shift at the top of this cascade by enabling natural deep-sleep entry, and the downstream effects (resolution, repair, hormone re-balance) flow from there. This is also why DSIP doesn’t sedate — it doesn’t impose sleep, it removes the regulatory friction that’s preventing the body from entering sleep on its own.
Sleep-hygiene foundations that have to be in place for DSIP to work (the “amplifies your system, doesn’t replace it” principle, made explicit):
- Devices off 2 hours before bed — blue-light suppresses melatonin onset; the cleaner this is, the more headroom DSIP has to work with.
- Caffeine cutoff 6+ hours before bed — adenosine clearance and sleep-onset latency; caffeine half-life is ~5-6 hours and tail-end exposure measurably degrades sleep architecture.
- Eating-window timing if you’re an intermittent faster — late-evening eating disrupts sleep architecture for some users; shifting the eating window earlier often improves sleep quality independently of DSIP.
If these foundations aren’t in place, DSIP may underperform — the peptide can amplify the regulatory shift but it can’t replace the inputs the nervous system is reading from the environment.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.
What should I avoid combining — and what's synergistic?
Stacking. DSIP pairs logically with the rest of the OHM sleep/circadian toolkit: with Selank when anxiety is what’s keeping you awake (calm the noise, then deepen the sleep), and conceptually alongside circadian foundations (light discipline, melatonin timing). Epithalon is the other Russian-school sleep/longevity-adjacent peptide worth knowing in this cluster. No controlled trial validates any DSIP combination — trial DSIP on its own first.
How can I buy this?
DSIP is available from US Pure Peptides — use code OHM20 for 20% off. US-manufactured, ISO 17025-accredited third-party COA testing on every batch, free bacteriostatic water included.
DSIP is also available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
| Best fit | People chasing deeper, more consolidated sleep — especially when stress, a shifted sleep phase, or “wired-but-tired” is the limiter. The peptide for the sleep-architecture question, not the knock-you-out question. The specific symptom phenotype to recognize (added 2026-06-24): wired but tired in the evening + consistently waking between 2-4 AM + poor recovery despite “doing everything right” on sleep hygiene + nutrition + exercise. The 2-4 AM wake pattern is a direct read on cortisol dysregulation (elevated nighttime cortisol from a flattened diurnal rhythm). |
| Evidence base | Small and old: a handful of 1980s–early-90s human studies (mostly one investigator group), split between positive open-label results and weak/null double-blind results. No modern RCT. Tier C. |
| Typical use | ~100–250 mcg subcutaneously, 30–60 min before bed (community/vendor-monograph protocol — the original trials used IV in clinical settings) |
| Safety | Benign in the human record — main reported AE is occasional headache; no dependence, tolerance, or sedation hangover. Safety yellow on thinness of data, not on any harm signal |
| Regulatory | US: not FDA-approved. FDA Category 2 (Sept 2023): restricted from 503A compounding. Research-chemical channel only |
| Where to buy | US Pure Peptides — use code OHM20 for 20% off. Primary OHM vendor for DSIP. Also available at BioLongevity with OHM-15. Not in Alyve’s catalog. |
What it is
DSIP — Delta Sleep-Inducing Peptide — is one of the few sleep compounds that isn’t a drug bolted onto your nervous system from the outside. It’s a naturally occurring neuropeptide your own brain makes. It was discovered in 1977 when Schoenenberger and Monnier pulled it from the blood of rabbits whose brains had been stimulated into deep, delta-wave (slow-wave) sleep — and named it for exactly what it appeared to do: induce delta sleep.
Structurally it’s a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) exact sequence. The pitch is appealing: a signal the body already uses to organize deep sleep, given back to you. The honest reality is more interesting and more humble than the marketing — DSIP has a real but thin human track record, and the evidence is genuinely mixed. This article gives you the real picture so you can decide with your eyes open.
DSIP sits at the sleep anchor of the OHM cognitive/sleep cluster. Where Selank calms the mental noise that keeps you up and Semax is daytime clarity, DSIP is aimed straight at sleep itself — specifically at sleep architecture (how deep and how consolidated), not at sedation.
How it works
Here’s the part most write-ups skip: DSIP’s mechanism is genuinely under-characterized, and the honest sources say so. A 2009 anaesthesia study flatly noted DSIP “lacks documented intrinsic biological activity in controlled studies” (PMID 19142086) — meaning there is no clean, agreed-upon receptor story for it the way there is for, say, a benzodiazepine or melatonin.
What’s proposed, across the literature:
- Modulation of delta-wave (slow-wave) sleep architecture — the original rationale and the namesake effect. The idea is that DSIP nudges sleep toward deeper, more consolidated stages rather than knocking you unconscious. mechanism.
- HPA-axis / stress-hormone modulation — DSIP has been studied for effects on the cortisol/ACTH stress axis. The human data here are themselves mixed: one study found DSIP decreased ACTH (Chiodera 1994, PMID 7698722) while another found no effect on CRH- or meal-induced ACTH/cortisol (Späth-Schwalbe 1995, PMID 7777652). So the “stress-buffering” story is plausible but unproven.
- Possible weak opiate-receptor activity — proposed off the back of the withdrawal-syndrome work (below), where DSIP blunted somatic withdrawal symptoms. mechanism.
- Antioxidant / stress-protective / thermoregulatory effects in preclinical models.
The takeaway: DSIP behaves like a sleep- and stress-modulator — it seems to do more in a disturbed system than a healthy one — but the receptor-level mechanism is an open question, not settled science. That uncertainty is part of why it grades Tier C.
What the research shows
DSIP’s human literature is small, mostly from the 1980s and early 1990s, dominated by one investigator group, and split down the middle. Both halves below are real and both matter.
The positive signal (open-label / single-arm: weaker designs):
- Schneider-Helmert & Schoenenberger 1981 — synthetic DSIP in 6 chronic insomniacs produced longer sleep, higher sleep quality, fewer interruptions, slightly more REM, and no daytime sedation (PMID 7028502).
- Kaeser 1984 — 7 severe-insomnia patients given 10 DSIP injections; sleep normalized in 6 of 7 over a 3–7 month follow-up, with improved daytime mood and performance (PMID 6391926).
- Schneider-Helmert 1987 — 14 chronic insomniacs over 7 nights: improved night-sleep efficiency and daytime alertness (PMID 3622582).
- Schneider-Helmert et al. 1987 — a delayed-sleep-phase case where DSIP advanced the main sleep phase by 5 hours and enabled an abrupt, clean withdrawal from a sleeping pill (flunitrazepam) (PMID 3582201). This “phase-shifting” result is the most distinctive thing in the DSIP file.
The counterweight (the better-controlled, double-blind designs: and they’re more sobering):
- Bes et al. 1992 — double-blind, 16 chronic insomniacs over 5 nights: DSIP showed only weak effects on sleep efficiency and latency, “unlikely to provide major therapeutic benefit” for chronic insomnia (PMID 1299794).
- Monti et al. 1987 — DSIP increased NREM and stage-2 sleep, but the differences from placebo lacked clinical significance (PMID 3583493).
- Pomfrett et al. 2009 — as an anaesthesia adjunct (n=24), DSIP paradoxically reduced anaesthetic depth and delta rhythm (PMID 19142086).
Beyond sleep: two genuinely interesting human signals:
- Withdrawal syndromes. Dick, Grandjean & Tissot 1983 gave IV DSIP to patients in alcohol and opiate withdrawal (49 evaluable); 48 of 49 improved, with rapid onset and lasting relief of the physical withdrawal symptoms, and no major side effects (PMID 6328354).
- Chronic pain. Larbig et al. 1984 — a 7-patient pilot in migraine, vasomotor headache, tinnitus, and psychogenic pain: IV DSIP significantly lowered pain in 6 of 7, with concurrent improvement in depressive symptoms (PMID 6548970).
The honest bottom line. The strongest sleep results come from one research group in open or low-sample designs; the moment you move to rigorous double-blind testing, the effect shrinks to weak or not-clinically-meaningful. The withdrawal and pain pilots are intriguing but tiny. There is no modern, well-powered RCT of DSIP. That is precisely a Tier C picture — real, suggestive, under-powered, and unresolved. DSIP earns its place as the named delta-sleep neuropeptide and the sleep anchor of this cluster; it does not earn the “clinically proven sleep aid” label, and OHM won’t give it one.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. DSIP is sold for research use only and is not an FDA-approved drug. This is not medical advice. Consult a qualified physician before beginning any protocol.
Route. The 1980s clinical studies used intravenous DSIP in a clinical setting. The modern at-home community route is subcutaneous injection — that’s a real gap to be aware of: the home protocol isn’t the route the trials validated.
Reconstitution. DSIP ships as a lyophilized powder. Reconstitute with bacteriostatic water; refrigerate after mixing; protect from light.
Community-standard protocol (vendor-monograph / practitioner tier —, not trial-derived):
- Dose: ~100–250 mcg, most commonly starting at 100 mcg and titrating up by response.
- Timing: 30–60 minutes before bed, once nightly.
- Cycle: typically run in short blocks (roughly 1–4 weeks) rather than indefinitely, then assess. against a primary protocol source.
What to expect: and what not to. DSIP is not a sedative. It won’t drop you like a benzodiazepine or a strong dose of trazodone. The reported effect is deeper, more consolidated sleep and easier mornings — and given the evidence, it’s reasonable to treat your own response over 1–2 weeks as the real test. If nothing changes, it isn’t working for you; the data say that’s a real possibility.
Use it as a reset tool, not a crutch. Jones (2026) articulates the cleanest rule for how to think about DSIP cycling: “Use it for a rough stretch — 4 to 6 weeks during high stress, post-surgery, loss, life disruption — then you get off it. The body adapts, so use it like a reset tool, not a crutch to continually get good sleep.” Mechanistically he reframes DSIP not as literally reproducing delta waves but as “sending a biochemical signal that your system interprets as ‘time to get to deep restorative sleep’” — useful framing for explaining what users actually feel vs. what’s electrically happening in the EEG. Patients tracking on Oura rings often see deep-sleep numbers move within a few nights. Maps cleanly to the short-block cycling already in the protocol above.
The nervous-system-first hierarchy framing (added 2026-06-24). A useful editorial reframe: DSIP is best understood not as a sleep supplement but as a nervous-system-regulation tool whose highest-leverage downstream effect is deep sleep. The mechanistic logic: chronic stress → cortisol elevated/dysregulated → sympathetic dominance + reduced parasympathetic tone → blood flow redirected from digestion + healing toward survival → mitochondrial efficiency declines → sleep architecture is disrupted → inflammatory signaling becomes altered → recovery capacity drops. DSIP supports the regulatory shift at the top of this cascade by enabling natural deep-sleep entry, and the downstream effects (resolution, repair, hormone re-balance) flow from there. This is also why DSIP doesn’t sedate — it doesn’t impose sleep, it removes the regulatory friction that’s preventing the body from entering sleep on its own.
Sleep-hygiene foundations that have to be in place for DSIP to work (the “amplifies your system, doesn’t replace it” principle, made explicit):
- Devices off 2 hours before bed — blue-light suppresses melatonin onset; the cleaner this is, the more headroom DSIP has to work with.
- Caffeine cutoff 6+ hours before bed — adenosine clearance and sleep-onset latency; caffeine half-life is ~5-6 hours and tail-end exposure measurably degrades sleep architecture.
- Eating-window timing if you’re an intermittent faster — late-evening eating disrupts sleep architecture for some users; shifting the eating window earlier often improves sleep quality independently of DSIP.
If these foundations aren’t in place, DSIP may underperform — the peptide can amplify the regulatory shift but it can’t replace the inputs the nervous system is reading from the environment.
Stacking. DSIP pairs logically with the rest of the OHM sleep/circadian toolkit: with Selank when anxiety is what’s keeping you awake (calm the noise, then deepen the sleep), and conceptually alongside circadian foundations (light discipline, melatonin timing). Epithalon is the other Russian-school sleep/longevity-adjacent peptide worth knowing in this cluster. No controlled trial validates any DSIP combination — trial DSIP on its own first.
Side effects & management
DSIP is one of the more benign molecules in its record — the limitation is evidence, not toxicity.
- Headache — the one AE that actually shows up (a few patients in the Dick withdrawal cohort). Usually minor.
- No dependence, no tolerance, no withdrawal, no morning hangover/sedation documented — unlike sleeping pills, this is not a CNS-depressant profile.
- No hepatotoxicity or cardiovascular signal in the (small) human record.
- The realistic “side effect” for most people is simpler: it may just not do much. The double-blind data make that a genuine possibility, so don’t keep chasing the dose upward if a fair trial does nothing.
Storage: refrigerate after reconstitution; protect from light; use within the typical compounding/label window.
Regulatory status
US: Not FDA-approved for any indication. Not a controlled substance. As of September 29, 2023, FDA placed DSIP (nominated as “Emideltide”) on the Category 2 bulk-drug-substances list — substances FDA has flagged with significant-safety-concern questions, which means it is not permitted for 503A compounding. (Semax and Selank acetate were added in the same action.) Practically: DSIP is not available through a compounding pharmacy the way some peptides are — it’s accessible only through the research-chemical channel, “not for human consumption.” This is an active regulatory area; the broader peptide-compounding question is on the FDA’s pharmacy-compounding advisory agenda.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.
| Field | Value |
|---|---|
| Molecular formula | C35H48N10O15 (PubChem CID 68816) |
| Average MW | 848.81 g/mol |
| CAS | 62568-57-4 |
| Sequence | WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) |
| HPLC purity criterion | RP-HPLC (C18, ACN/water + 0.1% TFA), UV 214 + 280 nm (Trp); ≥95% by peak area; single major peak ~12–16 min |
| MS identity | ESI-MS [M+H]+ 849.8, [M+2H]2+ 425.4; MALDI-TOF (CHCA/DHB); MS/MS for sequence confirmation |
| Counterion / net peptide | TFA or acetate counter-ion (synthesis/purification), can be 10–30% of lyophilized mass; net acidic (Asp/Glu), pI ~3.5–4.0 |
| Storage / reconstitution | Lyophilized at −20°C/−80°C, desiccated, light-protected (Trp photo-oxidation); reconstitute slowly down vial side, swirl not shake; refrigerate after mixing |
| Degradation / stability | Optimal pH 3.0–6.0; degrades >pH 8.0 (deamidation, oxidation); Trp oxidation, Asp-site hydrolysis, aggregation are the main pathways |
Primary-literature citation leads (PeptideBiologix; confirm before citing): Kovalzon & Strekalova 2006 (J Neurochem 97(2):303–9, “DSIP: a still unresolved riddle”); Bes et al. 1992 (Neuropsychobiology 26(4):193–7); withdrawal-syndrome study PMID 6548969; chronic-pain pilot PMID 6548970.
Sources
- research note backing this article (peptidelist scrape + PubMed verification + FDA Category 2 confirmation).
- thepeptidelist.com directory entry (30 studies cited / 16 human; site grade “moderate”); its 10 key-study PMIDs were independently confirmed.
- sleep-PRIMARY / Tier C / safety-yellow grading.
- PubMed primary literature: 7028502 (Schneider-Helmert 1981), 6391926 (Kaeser 1984), 3622582 (Schneider-Helmert 1987), 3582201 (phase-shift case 1987), 6328354 (Dick 1983, withdrawal), 6548970 (Larbig 1984, pain), 1299794 (Bes 1992, double-blind weak), 3583493 (Monti 1987, not clinically significant), 19142086 (Pomfrett 2009), 7777652 / 7698722 / 8475226 / 8175965 / 9606527 / 1475566 (endocrine + correlational).
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Dr. Lara May 16-min solo episode on DSIP in the context of nervous-system regulation. Source of the “wired but tired + waking 2-4 AM + poor recovery despite doing everything right” user-identification phenotype now in the Best-fit row above, the nervous-system-first hierarchy framing added to the Real-world protocol section, and the explicit sleep-hygiene foundation list (devices off 2 hr before bed, caffeine cutoff 6 hr, eating-window timing). No new science citations were added — May’s coverage confirms and rebrands the existing wiki’s -anchored evidence record (Chiodera 1994, Späth-Schwalbe 1995, Bes 1992, Monti 1987, Pomfrett 2009, Schneider-Helmert/Kaeser positive open-label set, Dick 1983 withdrawal, Larbig 1984 pain). ✅ no verification needed this pass.
Related: Selank · Semax · Epithalon · the Khavinson cognitive peptides (Pinealon, Cortagen).
Sources & references
- research note backing this article (peptidelist scrape + PubMed verification + FDA Category 2 confirmation).
- thepeptidelist.com directory entry (30 studies cited / 16 human; site grade “moderate”); its 10 key-study PMIDs were independently confirmed.
- sleep-PRIMARY / Tier C / safety-yellow grading.
- PubMed primary literature: 7028502 (Schneider-Helmert 1981), 6391926 (Kaeser 1984), 3622582 (Schneider-Helmert 1987), 3582201 (phase-shift case 1987), 6328354 (Dick 1983, withdrawal), 6548970 (Larbig 1984, pain), 1299794 (Bes 1992, double-blind weak), 3583493 (Monti 1987, not clinically significant), 19142086 (Pomfrett 2009), 7777652 / 7698722 / 8475226 / 8175965 / 9606527 / 1475566 (endocrine + correlational).
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Dr. Lara May 16-min solo episode on DSIP in the context of nervous-system regulation. Source of the “wired but tired + waking 2-4 AM + poor recovery despite doing everything right” user-identification phenotype now in the Best-fit row above, the nervous-system-first hierarchy framing added to the Real-world protocol section, and the explicit sleep-hygiene foundation list (devices off 2 hr before bed, caffeine cutoff 6 hr, eating-window timing). No new science citations were added — May’s coverage confirms and rebrands the existing wiki’s -anchored evidence record (Chiodera 1994, Späth-Schwalbe 1995, Bes 1992, Monti 1987, Pomfrett 2009, Schneider-Helmert/Kaeser positive open-label set, Dick 1983 withdrawal, Larbig 1984 pain). ✅ no verification needed this pass.
Related: Selank · Semax · Epithalon · the Khavinson cognitive peptides (Pinealon, Cortagen).
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout — user-reported experiences, not clinical data Last updated: 2026-07-10 Cross-refs:
[Epithalon](/peptides/epithalon/)·[Selank](/peptides/selank/)·*circadian-sleep*
Who reports the strongest results
Community consensus is consistent: DSIP works best for people who can fall asleep but can’t stay there — specifically the 2–4 AM cortisol-driven waking pattern. High-stress users (entrepreneurs, athletes, shift workers) report the most meaningful results. People without existing sleep disruption report little benefit.
What the community actually says
Sleep depth, not sleep initiation
The defining characterization across r/Peptides, r/nootropics, and peptide forums: “It doesn’t help me fall asleep, but it helps me stay in deep sleep.”
- Reduced or eliminated middle-of-the-night waking, especially the 2–4 AM cortisol window — reported by roughly 40–50% of users
- Effects build cumulatively over 2–4 weeks; acute response on night one is not the typical experience
- Vivid but non-distressing dreams early in the cycle — typically resolves within the first few nights
- One Oura Ring user documented approximately 40 additional minutes of combined deep sleep and REM per night, with a stable 7:15–7:45 AM natural wake time established
- Consistently contrasted with prescription sleep drugs: described as biasing the brain toward slow-wave (delta) sleep once onset happens naturally — not forcing sedation
No hangover — a standout advantage
Absence of morning grogginess is one of the most-cited differentiators, particularly among users comparing DSIP to benzodiazepines or Z-drugs. At appropriate doses, users describe waking rested rather than sedated — without the withdrawal rebound that prescription options carry.
Cortisol and stress as a secondary benefit
A consistent subset of users — high-stress professionals in particular — report that DSIP’s most noticeable effect is not sleep duration but stress reactivity: described as “lowered reactivity, not artificial calm.” Sleep improvements often follow as a downstream effect.
Protocol as used by the community
Dose range:
- Start: 100–200 mcg SubQ, 30–60 minutes before bed
- Effective range: 200–300 mcg for most users
- Above 300 mcg: effects plateau; side effects increase without added benefit
- Note: Clinical IV dosing (≈21 mcg/kg, or 1–2 mg for adults) is far higher than effective SubQ community doses
Route comparison:
- SubQ: 60–70% response rate
- Nasal spray: 40–50% response rate
- Oral/sublingual: 20–30% — peptide degrades significantly in the GI tract
Timing is critical: 30–60 minutes pre-bed. Accidental daytime dosing at 3 mg produced all-day sedation without sleep benefit in one documented account — confirming biological-night timing dependency.
Cycling:
- Most common: 5 nights on / 2 off, for 8 weeks → 8 weeks off
- Shorter protocols also used: 2–4 weeks on / 2 off
- Community reports 2–4 weeks of continued benefit after stopping before sleep returns to baseline
Critical stability note: DSIP loses 40–60% potency within 72 hours in bacteriostatic water at refrigerator temperature. Community fix: reconstitute smaller volumes and use within 3–4 days. Many “didn’t work” reports are attributed to degraded product — not receptor non-response or true tolerance.
Side effects and risk signals
Overall profile is mild relative to GABAergic sleep drugs.
| Effect | Pattern |
|---|---|
| Headache | Most frequently reported; clearly dose-dependent. 1 mg → persistent headaches, resolved at 0.5 mg. 2 mg → three-day headache and hangover. |
| Morning grogginess | Dose-dependent; absent at appropriate SubQ doses; cited as the key prescription-drug differentiator |
| Vivid dreams | Uncommon; typically resolves within first few nights of a cycle |
| Nausea / mild GI | Occasional; rare at lower doses |
| Paradoxical insomnia | Rare; attributed to U-shaped dose-response curve |
| Daytime sedation | At high dose or wrong timing; confirms timing dependency |
| Non-response | 35–45% report no measurable effect — described as neutral, not adverse; no rebound insomnia or withdrawal noted |
Frequently asked questions (community version)
What’s different from melatonin? Melatonin manages circadian timing (when you sleep). DSIP affects sleep architecture (how deep and continuous). Community recommendation: melatonin for jet lag or circadian disruption; DSIP when circadian timing isn’t the problem but quality and depth are.
Why did it stop working? In most “tolerance” debates, the community points to peptide degradation — reconstituting too large a volume and using degraded product by day 3–4 — rather than true receptor tolerance. Reconstitute smaller amounts every 3–4 days and revisit before concluding tolerance.
Does it work for people with healthy sleep? Community consensus: probably not significantly. DSIP’s strongest signal is in sleep already disrupted by stress, cortisol dysregulation, or chronic waking patterns.
Can I stack it with melatonin, magnesium, or GABA? Community widely stacks these without adverse interaction reports. DSIP addresses architecture; the others address onset and sedation — they occupy different lanes.
Notable community accounts
- Oura Ring tracker: ~40 additional minutes of combined deep sleep and REM per night; stable 7:15–7:45 AM natural wake time established across the cycle
- Stress-first reporter: Primary reported benefit was cortisol reactivity reduction and emotional regulation; sleep improvement was secondary
- Accidental 3 mg daytime dose: “Lucid and out of it all day, couldn’t stay awake” — confirms biological-night timing dependency
- Dose-headache pattern: 1 mg → persistent headaches → dropped to 0.5 mg → workable; 2 mg → three-day headache effect
- Single-bottle carry-over: User stopped after one bottle; sleep improvements persisted for weeks before gradually returning to baseline
- “Next level sleep”: User at 0.75 mg ranked DSIP in top four substances tried; described sleep depth as qualitatively different from anything baseline
How DSIP compares (community lens)
| Approach | Community read |
|---|---|
| Melatonin | Circadian/onset tool; DSIP for depth when timing isn’t the problem |
| Prescription Z-drugs / benzos | Suppress deep sleep; DSIP increases it — described as “the opposite pharmacological direction” |
| Epithalon | Also sleep-affecting via pineal/melatonin axis; some stack both for combined effect |
| Selank | Targets anxiety-mediated sleep disruption; complementary mechanism for stress-driven insomnia |
Cross-references
[Epithalon](/peptides/epithalon/)— alternative or stacking option for sleep architecture and longevity[Selank](/peptides/selank/)— anxiety-mediated sleep disruption; complementary pairing*circadian-sleep*— the whole-body sleep context DSIP sits within
Commercial note
DSIP is available through Alyve — use code OHM-15 at checkout for 15% off.
Cost context from community: compounded DSIP runs approximately $150–300/month, which limits long-term use for many users compared to melatonin ($5–30 OTC). The community positions DSIP as a targeted intervention for stress-driven sleep disruption rather than a daily maintenance supplement.